Experienced in Tongue Cancer

Dr. Manish S. Bhandari

Oncology | Hematology Oncology
St Elizabeth Medical Center, Inc
1 Medical Village Dr, 
Edgewood, KY 
Accepting New Patients
Experienced in Tongue Cancer
St Elizabeth Medical Center, Inc
1 Medical Village Dr, 
Edgewood, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Manish Bhandari is an Oncologist and a Hematologist Oncology provider in Edgewood, Kentucky. Dr. Bhandari is rated as an Experienced provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Adult Soft Tissue Sarcoma, Bone Graft, and Vertebroplasty. Dr. Bhandari is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
St Elizabeth Florence
St Elizabeth Edgewood
St Elizabeth Ft Thomas
Languages Spoken
English
Hindi
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

ST ELIZABETH MEDICAL CENTER, INC
1 Medical Village Dr, Edgewood, KY 41017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) Subjects With Cancers
A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) Subjects With Cancers
Enrollment Status: No_longer_available
Publish Date: August 18, 2020
Intervention Type: Drug
View 2 Less Clinical Trials

1 Total Publications

Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
Journal: The American journal of case reports
Published: July 05, 2018
Similar Doctors
Experienced in Tongue Cancer
Dr. Muhammad K. Riaz
Hematology Oncology | Hematology | Oncology
Experienced in Tongue Cancer
Dr. Muhammad K. Riaz
Hematology Oncology | Hematology | Oncology

St Elizabeth Medical Center, Inc

85 N Grand Ave, 
Fort Thomas, KY 
 (6.8 miles away)
859-572-3100
Languages Spoken:
English, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Muhammad Riaz is a Hematologist Oncology specialist and a Hematologist in Fort Thomas, Kentucky. Dr. Riaz is rated as a Distinguished provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC). Dr. Riaz is currently accepting new patients.

Experienced in Tongue Cancer
Dr. Keren B. Sturtz
Hematology Oncology | Hematology | Oncology
Experienced in Tongue Cancer
Dr. Keren B. Sturtz
Hematology Oncology | Hematology | Oncology
2139 Auburn Ave, 
Cincinnati, OH 
 (8.0 miles away)
513-321-4333
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Keren Sturtz is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Sturtz is rated as an Experienced provider by MediFind in the treatment of Tongue Cancer. Her top areas of expertise are Hairy Cell Leukemia (HCL), Breast Cancer, Tongue Cancer, and Lung Cancer. Dr. Sturtz is currently accepting new patients.

Advanced in Tongue Cancer
Dr. Trisha Wise
Hematology | Oncology
Advanced in Tongue Cancer
Dr. Trisha Wise
Hematology | Oncology

University Of Cincinnati Physicians Company LLC

3188 Bellevue Ave, 
Cincinnati, OH 
 (8.3 miles away)
513-584-1000
Languages Spoken:
English
See accepted insurances

Trisha Wise is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Wise is rated as a Distinguished provider by MediFind in the treatment of Tongue Cancer. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhandari's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 30 Advanced Conditions
    View All 129 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile